<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DEPO-ESTRADIOL- estradiol cypionate injection </strong><br>Pharmacia and Upjohn Company<br></p></div>
<h1>DEPO<span class="Sup">®</span>-ESTRADIOL <br>Estradiol cypionate injection, USP</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="boxed_warning"></a><a name="section-1"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.1"></a><p></p>
<h2>ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER</h2>
<p class="First">Close clinical surveillance of all women taking estrogens is important. Adequate diagnostic measures including endometrial sampling, when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>. There is currently no evidence that the use of "natural" estrogens results in a different endometrial risk profile than "synthetic" estrogens at equivalent estrogen doses. <span class="Bold">(See <a href="#warnings_malignant_endometrial">WARNINGS, malignant neoplasms, Endometrial cancer</a>.)</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.2"></a><p></p>
<h2>CARDIOVASCULAR AND OTHER RISKS</h2>
<p class="First">Estrogens with and without progestins should not be used for the prevention of cardiovascular disease. <span class="Bold">(See <a href="#warnings_cardiovascular">WARNINGS, <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular disorders</span></a>.)</span></p>
<p>The Women's Health Initiative (WHI) study reported increased risks of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, invasive breast cancer, pulmonary emboli, and <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> in postmenopausal women (50 to 79 years of age) during 5 years of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone acetate (MPA 2.5 mg) relative to placebo. (See <span class="Bold"><a href="#clinical_pharmacology_clinical">CLINICAL PHARMACOLOGY, Clinical Studies.</a></span>)</p>
<p>The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported increased risk of developing probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in postmenopausal women 65 years of age or older during 4 years of treatment with oral conjugated estrogens plus medroxyprogesterone acetate relative to placebo. It is unknown whether this finding applies to younger postmenopausal women or to women taking estrogen-alone therapy. (See <span class="Bold"><a href="#clinical_pharmacology_clinical">CLINICAL PHARMACOLOGY, Clinical Studies</a>.)</span></p>
<p>Other doses of conjugated estrogens with medroxyprogesterone acetate, and other combinations and dosage forms of estrogens and progestins were not studied in the WHI clinical trials and, in the absence of comparable data, these risks should be assumed to be similar. Because of these risks, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">DEPO-Estradiol Injection contains estradiol cypionate for intramuscular use. Each mL contains:</p>
<p>5 mg/mL—5 mg estradiol cypionate, 5.4 mg chlorobutanol anhydrous (chloral derivative) added as preservative; in 913 mg cottonseed oil.</p>
<p><span class="Bold">Warning:</span> Chlorobutanol may be habit forming. The structural formula is represented below:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9a4229fd-fecd-4ac1-9c4f-6d442533457f&amp;name=depo-estradiol-01.jpg"></div>
<p>DEPO-Estradiol contains an oil soluble ester of estradiol 17β. The chemical name for estradiol cypionate is estradiol 17-cyclopentanepropionate.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level.</p>
<p>The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>, most endogenous estrogen is produced by conversion of androstenedione, secreted by the adrenal cortex, to estrone by peripheral tissues. Thus, estrone and the sulfate conjugated form, estrone sulfate, are the most abundant circulating estrogens in postmenopausal women.</p>
<p>Estrogens act through binding to nuclear receptors in estrogen-responsive tissues. To date, two estrogen receptors have been identified. These vary in proportion from tissue to tissue.</p>
<p>Circulating estrogens modulate the pituitary secretion of the gonadotropins, luteinizing hormone (LH) and follicle stimulating hormone (FSH), through a negative feedback mechanism. Estrogens act to reduce the elevated levels of these hormones seen in postmenopausal women.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1"></a><p></p>
<h2>Absorption</h2>
<p class="First">When conjugated with aryl and alkyl groups for parenteral administration, the rate of absorption of oily preparations is slowed with a prolonged duration of action, such that a single intramuscular injection of estradiol valerate or estradiol cypionate is absorbed over several weeks.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2"></a><p></p>
<h2>Distribution</h2>
<p class="First">The distribution of exogenous estrogens is similar to that of endogenous estrogens. Estrogens are widely distributed in the body and are generally found in higher concentrations in the sex hormone target organs. Estrogens circulate in the blood largely bound to <span class="product-label-link" type="condition" conceptid="4206320" conceptname="Sex steroid binding globulin">sex hormone binding globulin</span> (SHBG) and albumin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3"></a><p></p>
<h2>Metabolism</h2>
<p class="First">Exogenous estrogens are metabolized in the same manner as endogenous estrogens. Circulating estrogens exist in a dynamic equilibrium of metabolic interconversions. These transformations take place mainly in the liver. Estradiol is converted reversibly to estrone, and both can be converted to estriol, which is the major urinary metabolite. Estrogens also undergo enterohepatic recirculation via sulfate and glucuronide conjugation in the liver, biliary secretion of conjugates into the intestine, and hydrolysis in the gut followed by reabsorption. In postmenopausal women, a significant proportion of the circulating estrogens exist as sulfate conjugates, especially estrone sulfate, which serves as a circulating reservoir for the formation of more active estrogens.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.4"></a><p></p>
<h2>Excretion</h2>
<p class="First">Estradiol, estrone, and estriol are excreted in the urine along with glucuronide and sulfate conjugates.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.5"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">In vitro and in vivo studies have shown that estrogens are metabolized partially by cytochrome P450 3A4 (CYP3A4). Therefore, inducers or inhibitors of CYP3A4 may affect estrogen drug metabolism. Inducers of CYP3A4 such as St. John's Wort preparations (Hypericum perforatum), phenobarbital, carbamazepine, and rifampin may reduce plasma concentrations of estrogens, possibly resulting in a decrease in therapeutic effects and/or changes in the <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span> profile. Inhibitors of CYP3A4 such as erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir and grapefruit juice may increase plasma concentrations of estrogens and may result in side effects.</p>
<p>Estrogen drug products administered by non oral routes are not subject to first-pass metabolism, but also undergo significant hepatic uptake, metabolism, and enterohepatic recycling.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="clinical_pharmacology_clinical"></a><a name="section-2.6"></a><p></p>
<h2>Clinical Studies</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.6.1"></a><p></p>
<h3>Women's Health Initiative Studies</h3>
<p class="First">The Women's Health Initiative (WHI) enrolled a total of 27,000 predominantly healthy postmenopausal women to assess the risks and benefits of either the use of 0.625 mg conjugated estrogens (CE) per day alone or the use of oral 0.625 mg conjugated estrogens plus 2.5 mg medroxyprogesterone acetate (MPA) per day compared to placebo in the prevention of certain chronic diseases. The primary endpoint was the incidence of coronary heart disease (CHD) (nonfatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>), with invasive breast cancer as the primary adverse outcome studied. A "global index" included the earliest occurrence of CHD, invasive breast cancer, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (PE), endometrial cancer, colorectal cancer, <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fracture</span>, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to other cause. The study did not evaluate the effects of CE or CE/MPA on <span class="product-label-link" type="condition" conceptid="439082" conceptname="Menopausal syndrome">menopausal symptoms</span>.</p>
<p>The CE/MPA substudy was stopped early because, according to the predefined stopping rule, the increased risk of breast cancer and cardiovascular events exceeded the specified benefits included in the "global index." Results of the CE/MPA substudy, which included 16,608 women (average age of 63 years, range 50 to 79; 83.9% White, 6.5% Black, 5.5% Hispanic), after an average follow-up of 5.2 years are presented in Table 1 below:</p>
<table width="100%">
<caption><span>Table 1: RELATIVE AND ABSOLUTE RISK SEEN IN THE CE/MPA SUBSTUDY OF WHI <a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></span></caption>
<col align="left" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<thead>
<tr class="First">
<th class="Lrule" align="left" rowspan="2" valign="top">Event <a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>
</th>
<th class="Lrule" align="center" rowspan="2">Relative Risk<br>CE/MPA vs placebo<br>at 5.2 Years<br>(95% CI<a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a>)</th>
<th class="Lrule" align="center" valign="top">Placebo<br>n = 8102</th>
<th class="Lrule Rrule" align="center" valign="top">CE/MPA<br>n = 8506</th>
</tr>
<tr class="Last"><th class="Lrule Rrule Toprule" align="center" colspan="2" valign="top">Absolute Risk per 10,000 Person-years</th></tr>
</thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>adapted from JAMA, 2002; 288:321–333</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>a subset of the events was combined in a "global index," defined as the earliest occurrence of CHD</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>nominal confidence intervals unadjusted for multiple looks and multiple comparisons</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">§</a></dt>
<dd>includes metastatic and non-metastatic breast cancer with the exception of in situ breast cancer</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">¶</a></dt>
<dd>not included in Global Index</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule" align="left">CHD events</td>
<td class="Lrule" align="center">1.29 (1.02–1.63)</td>
<td class="Lrule" align="center">30</td>
<td class="Lrule Rrule" align="center">37</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="Italics">Non-fatal MI</span>
</td>
<td class="Lrule" align="center"><span class="Italics">1.32 (1.02–1.72)</span></td>
<td class="Lrule" align="center"><span class="Italics">23</span></td>
<td class="Lrule Rrule" align="center"><span class="Italics">30</span></td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">  <span class="Italics">CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></span>
</td>
<td class="Botrule Lrule" align="center"><span class="Italics">1.18 (0.70–1.97)</span></td>
<td class="Botrule Lrule" align="center"><span class="Italics">6</span></td>
<td class="Botrule Lrule Rrule" align="center"><span class="Italics">7</span></td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">Invasive breast cancer <a name="footnote-reference-4" href="#footnote-4" class="Sup">§</a>
</td>
<td class="Botrule Lrule" align="center">1.26 (1.00–1.59)</td>
<td class="Botrule Lrule" align="center">30</td>
<td class="Botrule Lrule Rrule" align="center">38</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span></td>
<td class="Botrule Lrule" align="center">1.41 (1.07–1.85)</td>
<td class="Botrule Lrule" align="center">21</td>
<td class="Botrule Lrule Rrule" align="center">29</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary embolism</span></td>
<td class="Botrule Lrule" align="center">2.13 (1.39–3.25)</td>
<td class="Botrule Lrule" align="center">8</td>
<td class="Botrule Lrule Rrule" align="center">16</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">Colorectal cancer</td>
<td class="Botrule Lrule" align="center">0.63 (0.43–0.92)</td>
<td class="Botrule Lrule" align="center">16</td>
<td class="Botrule Lrule Rrule" align="center">10</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">Endometrial cancer</td>
<td class="Botrule Lrule" align="center">0.83 (0.47–1.47)</td>
<td class="Botrule Lrule" align="center">6</td>
<td class="Botrule Lrule Rrule" align="center">5</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">Hip fracture</span></td>
<td class="Botrule Lrule" align="center">0.66 (0.45–0.98)</td>
<td class="Botrule Lrule" align="center">15</td>
<td class="Botrule Lrule Rrule" align="center">10</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> due to causes other than the events above</td>
<td class="Botrule Lrule" align="center" valign="top">0.92 (0.74–1.14)</td>
<td class="Botrule Lrule" align="center" valign="top">40</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">37</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">Global index <a href="#footnote-2" class="Sup">†</a>
</td>
<td class="Botrule Lrule" align="center">1.15 (1.03–1.28)</td>
<td class="Botrule Lrule" align="center">151</td>
<td class="Botrule Lrule Rrule" align="center">170</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="4"> </td></tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep vein thrombosis</span> <a name="footnote-reference-5" href="#footnote-5" class="Sup">¶</a>
</td>
<td class="Botrule Lrule" align="center">2.07 (1.49–2.87)</td>
<td class="Botrule Lrule" align="center">13</td>
<td class="Botrule Lrule Rrule" align="center">26</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4066995" conceptname="Fracture of vertebral column with spinal cord injury">Vertebral fractures</span> <a href="#footnote-5" class="Sup">¶</a>
</td>
<td class="Botrule Lrule" align="center">0.66 (0.44–0.98)</td>
<td class="Botrule Lrule" align="center">15</td>
<td class="Botrule Lrule Rrule" align="center">9</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="left">Other <span class="product-label-link" type="condition" conceptid="4188189" conceptname="Osteoporotic fracture">osteoporotic fractures</span> <a href="#footnote-5" class="Sup">¶</a>
</td>
<td class="Botrule Lrule" align="center" valign="top">0.77 (0.69–0.86)</td>
<td class="Botrule Lrule" align="center" valign="top">170</td>
<td class="Botrule Lrule Rrule" align="center" valign="top">131</td>
</tr>
</tbody>
</table>
<p>For those outcomes included in the "global index," the absolute excess risks per 10,000 person-years in the group treated with CE/MPA were 7 more CHD events, 8 more <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, 8 more PEs, and 8 more invasive breast cancers, while absolute risk reductions per 10,000 person-years were 6 fewer colorectal cancers and 5 fewer <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fractures</span>. The absolute excess risk of events included in the "global index" was 19 per 10,000 women-years. There was no difference between the groups in terms of all-cause mortality. (See <span class="Bold"><a href="#boxed_warning">BOXED WARNINGS</a>, <a href="#warnings">WARNINGS</a></span> and <span class="Bold"><a href="#precautions">PRECAUTIONS</a>.</span>)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.6.2"></a><p></p>
<h3>Women's Health Initiative Memory Study</h3>
<p class="First">The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, enrolled 4,532 predominantly healthy postmenopausal women 65 years of age and older (47% were age 65 to 69 years, 35% were 70 to 74 years, and 18% were 75 years of age and older) to evaluate the effects of CE/MPA (0.625 mg conjugated estrogens plus 2.5 mg medroxyprogesterone acetate) on the incidence of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (primary outcome) compared with placebo.</p>
<p>After an average follow-up of 4 years, 40 women in the estrogen/progestin group (45 per 10,000 women-years) and 21 in the placebo group (22 per 10,000 women-years) were diagnosed with probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. The relative risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in the hormone therapy group was 2.05 (95% CI, 1.21 to 3.48) compared to placebo. Differences between groups became apparent in the first year of treatment. It is unknown whether these findings apply to younger postmenopausal women. (See <span class="Bold"><a href="#boxed_warning">BOXED WARNINGS</a></span> and <span class="Bold"><a href="#warnings_dementia">WARNINGS, <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></a>.</span>)</p>
<p>Comparative clinical studies have demonstrated that estradiol cypionate produces estrogenic effects that are qualitatively the same as those produced by other estradiol esters. In menopausal women, the average duration of estrogenic effect (as measured by vaginal smear) following a single injection of 5 mg of estradiol cypionate was found to be approximately 3 to 4 weeks. Relief of vasomotor symptoms was observed to occur within 1 to 5 days and to be maintained for 1 to 8 weeks, with an average of approximately 5 weeks.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">DEPO-Estradiol Injection is indicated in the treatment of:</p>
<ol>
<li>Moderate to severe <span class="Italics">vasomotor</span> symptoms associated with the <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>.</li>
<li>Hypoestrogenism due to <span class="product-label-link" type="condition" conceptid="4167354" conceptname="Hypogonadism">hypogonadism</span>.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="contraindications"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Estrogens should not be used in individuals with any of the following conditions:</p>
<ol>
<li>Undiagnosed abnormal genital <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</li>
<li>Known or suspected cancer of the breast.</li>
<li>Known or suspected estrogen-dependent neoplasia.</li>
<li>Active <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> or history of these conditions.</li>
<li>Active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>).</li>
<li>Liver dysfunction or disease.</li>
<li>DEPO-Estradiol should not be used in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to its ingredients.</li>
<li>Known or suspected pregnancy. There is no indication for DEPO-Estradiol in pregnancy.</li>
</ol>
<p>There appears to be little or no increased risk of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> in children born to women who have used estrogens and progestins from oral contraceptives inadvertently during early pregnancy. (See <a href="#precautions">PRECAUTIONS</a>.)</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="warnings"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">See <span class="Bold"><a href="#boxed_warning">BOXED WARNINGS</a></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="warnings_cardiovascular"></a><a name="section-5.1"></a><p></p>
<h2>1. <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular disorders</span></h2>
<p class="First">Estrogen and estrogen/progestin therapy have been associated with an increased risk of cardiovascular events such as <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, as well as <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span> and <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (<span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">venous thromboembolism</span> or VTE). Should any of these occur or be suspected, estrogens should be discontinued immediately.</p>
<p>Risk factors for arterial vascular disease (e.g., <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, tobacco use, <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, and <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>) and/or <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">venous thromboembolism</span> (e.g., personal history or family history of VTE, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, and <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>) should be managed appropriately.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1.1"></a><p></p>
<h3>a. Coronary heart disease and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span></h3>
<p class="First">In the Women's Health Initiative (WHI) study, an increase in the number of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarctions</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> has been observed in women receiving CE compared to placebo. These observations are preliminary, and the study is continuing. (See <span class="Bold"><a href="#clinical_pharmacology_clinical">CLINICAL PHARMACOLOGY, Clinical Studies</a></span>.)</p>
<p>In the CE/MPA substudy of WHI, an increased risk of coronary heart disease (CHD) events (defined as nonfatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>) was observed in women receiving CE/MPA compared to women receiving placebo (37 vs. 30 per 10,000 women-years). The increase in risk was observed in year one and persisted.</p>
<p>In the same substudy of WHI, an increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> was observed in women receiving CE/MPA compared to women receiving placebo (29 vs. 21 per 10,000 women-years). The increase in risk was observed after the first year and persisted.</p>
<p>In postmenopausal women with documented heart disease (n = 2,763, average age 66.7 years) a controlled clinical trial of secondary prevention of cardiovascular disease (Heart and Estrogen/Progestin Replacement Study; HERS) treatment with CE/MPA (0.625 mg/2.5 mg per day) demonstrated no cardiovascular benefit. During an average follow-up of 4.1 years, treatment with CE/MPA did not reduce the overall rate of CHD events in postmenopausal women with established coronary heart disease. There were more CHD events in the CE/MPA-treated group than in the placebo group in year 1, but not during the subsequent years. Two thousand three hundred and twenty-one women from the original HERS trial agreed to participate in an open-label extension of HERS, HERS II. Average follow-up in HERS II was an additional 2.7 years, for a total of 6.8 years overall. Rates of CHD events were comparable among women in the CE/MPA group and the placebo group in HERS, HERS II, and overall.</p>
<p>Large doses of estrogen (5 mg conjugated estrogens per day), comparable to those used to treat cancer of the prostate and breast, have been shown in a large prospective clinical trial in men to increase the risks of nonfatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, and <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1.2"></a><p></p>
<h3>b. <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">Venous thromboembolism</span> (VTE)</h3>
<p class="First"><span class="Bold">In the Women's Health Initiative (WHI) study, in women receiving CE compared to placebo, the risk of VTE (including both DVT and PE) was increased 33% (28 vs. 21 per 10,000 person-years) although only the increased rate of DVT reached statistical significance (p = 0.03)</span>. (See <span class="Bold"><a href="#clinical_pharmacology_clinical">CLINICAL PHARMACOLOGY, Clinical Studies</a></span>.)</p>
<p>In the CE/MPA treatment substudy of WHI, a 2-fold greater rate of VTE, including deep <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span> and <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, was observed in women receiving treatment with CE/MPA compared to women receiving placebo. The rate of VTE was 34 per 10,000 woman-years in the CE/MPA group compared to 16 per 10,000 woman-years in the placebo group. The increase in VTE risk was observed during the first year and persisted.</p>
<p>If feasible, estrogens should be discontinued at least 4 to 6 weeks before surgery of the type associated with an increased risk of <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, or during periods of prolonged immobilization.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.2"></a><p></p>
<h2>2. Malignant neoplasms</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="warnings_malignant_endometrial"></a><a name="section-5.2.1"></a><p></p>
<h3>a. Endometrial cancer</h3>
<p class="First">The use of unopposed estrogens in women with intact uteri has been associated with an increased risk of endometrial cancer. The reported endometrial cancer risk among unopposed estrogen users was about 2-to-12-fold greater than in non-users, and appears dependent on duration of treatment and on estrogen dose. Most studies show no significant increased risk associated with use of estrogens for less than one year. The greatest risk appears associated with prolonged use, with increased risks of 15-to-24-fold for five to ten years or more and this risk has been shown to persist for at least 8 to 15 years after estrogen therapy is discontinued.</p>
<p>Clinical surveillance of all women taking estrogen/progestin combinations is important. Adequate diagnostic measures, including endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>. There is no evidence that the use of natural estrogens results in a different endometrial risk profile than synthetic estrogens of equivalent estrogen dose. Adding a progestin to estrogen therapy has been shown to reduce the risk of <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span>, which may be a precursor to endometrial cancer.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.2.2"></a><p></p>
<h3>b. Breast cancer</h3>
<p class="First">The use of estrogens and progestins by postmenopausal women has been reported to increase the risk of breast cancer. The most important randomized clinical trial providing information about this issue is the Women's Health Initiative (WHI) substudy of CE/MPA (see <span class="Bold"><a href="#clinical_pharmacology_clinical">CLINICAL PHARMACOLOGY, Clinical Studies</a></span>). The results from observational studies are generally consistent with those of the WHI clinical trial and report no significant variation in the risk of breast cancer among different estrogens or progestins, doses, or routes of administration.</p>
<p>The CE/MPA substudy of WHI reported an increased risk of breast cancer in women who took CE/MPA for a mean follow-up of 5.6 years. Observational studies have also reported an increased risk for estrogen/progestin combination therapy, and a smaller increased risk for estrogen-alone therapy, after several years of use. In the WHI trial and from observational studies, the excess risk increased with duration of use. From observational studies, the risk appeared to return to baseline in about five years after stopping treatment. In addition, observational studies suggest that the risk of breast cancer was greater, and became apparent earlier, with estrogen/progestin combination therapy as compared to estrogen-alone therapy.</p>
<p>In the CE/MPA substudy, 26% of the women reported prior use of estrogen-alone and/or estrogen/progestin combination hormone therapy. After a mean follow-up of 5.6 years during the clinical trial, the overall relative risk of invasive breast cancer was 1.24 (95% confidence interval 1.01–1.54), and the overall absolute risk was 41 vs. 33 cases per 10,000 women-years, for CE/MPA compared with placebo. Among women who reported prior use of hormone therapy, the relative risk of invasive breast cancer was 1.86, and the absolute risk was 46 vs. 25 cases per 10,000 women-years, for CE/MPA compared with placebo. Among women who reported no prior use of hormone therapy, the relative risk of invasive breast cancer was 1.09, and the absolute risk was 40 vs. 36 cases per 10,000 women-years for CE/MPA compared with placebo. In the same substudy, invasive breast cancers were larger and diagnosed at a more advanced stage in the CE/MPA group compared with the placebo group. <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">Metastatic disease</span> was rare with no apparent difference between the two groups. Other prognostic factors such as histologic subtype, grade and hormone receptor status did not differ between groups.</p>
<p>The use of estrogen plus progestin has been reported to result in an increase in abnormal mammograms requiring further evaluation. All women should receive yearly breast examinations by a healthcare provider and perform monthly breast self-examinations. In addition, mammography examinations should be scheduled based on patient age, risk factors, and prior mammogram results.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="warnings_dementia"></a><a name="section-5.3"></a><p></p>
<h2>3. <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></h2>
<p class="First">In the Women's Health Initiative Memory Study (WHIMS), 4,532 generally healthy postmenopausal women 65 years of age and older were studied, of whom 35% were 70 to 74 years of age and 18% were 75 or older. After an average follow-up of 4 years, 40 women being treated with CE/MPA (1.8%, n= 2,229) and 21 women in the placebo group (0.9%, n= 2,303) received diagnoses of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. The relative risk for CE/MPA versus placebo was 2.05 (95% confidence interval 1.21 – 3.48), and was similar for women with and without histories of menopausal hormone use before WHIMS. The absolute risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE/MPA versus placebo was 45 versus 22 cases per 10,000 women-years. It is unknown whether these findings apply to younger postmenopausal women. (See <span class="Bold"><a href="#clinical_pharmacology_clinical">CLINICAL PHARMACOLOGY, Clinical Studies</a></span> and <span class="Bold"><a href="#precautions_geriatric">PRECAUTIONS, Geriatric Use</a>.)</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.4"></a><p></p>
<h2>4. <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder disease</span></h2>
<p class="First">A 2- to 4-fold increase in the risk of <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span> requiring surgery in postmenopausal women receiving estrogen has been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.5"></a><p></p>
<h2>5. <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span></h2>
<p class="First">Estrogen administration may lead to severe <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> in patients with breast cancer and bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span>. If <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> occurs, use of the drug should be stopped and appropriate measures taken to reduce the serum calcium level.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.6"></a><p></p>
<h2>6. Visual abnormalities</h2>
<p class="First">Retinal vascular <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> has been reported in patients receiving estrogens. Discontinue medication pending examination if there is sudden partial or complete <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>, or a sudden onset of <span class="product-label-link" type="condition" conceptid="436700" conceptname="Exophthalmos">proptosis</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, or <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>. If examination reveals <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span> or retinal vascular lesions, estrogens should be permanently discontinued.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="precautions"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-6.1"></a><p></p>
<h2>A. General</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1"></a><p></p>
<h3>1. Addition of progestin when a woman has not had a hysterectomy</h3>
<p class="First">Studies of the addition of a progestin for 10 or more days of a cycle of estrogen administration, or daily with estrogen in a continuous regimen, have reported a lowered incidence of <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span> than would be induced by estrogen treatment alone. <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">Endometrial hyperplasia</span> may be a precursor to endometrial cancer.</p>
<p>There are, however, possible risks that may be associated with the use of progestins with estrogens compared to estrogen-alone regimens. These include a possible increased risk of breast cancer, adverse effects on lipoprotein metabolism (e.g., lowering HDL, raising LDL) and impairment of glucose tolerance.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.2"></a><p></p>
<h3>2. Elevated blood pressure</h3>
<p class="First">In a small number of case reports, substantial increases in blood pressure have been attributed to idiosyncratic reactions to estrogens. In a large, randomized, placebo-controlled clinical trial, a generalized effect of estrogens on blood pressure was not seen. Blood pressure should be monitored at regular intervals with estrogen use.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.3"></a><p></p>
<h3>3. <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span></h3>
<p class="First">In patients with pre-existing <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>, estrogen therapy may be associated with elevations of plasma triglycerides leading to <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> and other complications.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.4"></a><p></p>
<h3>4. <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">Impaired liver function</span> and past history of <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span></h3>
<p class="First">Estrogens may be poorly metabolized in patients with <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">impaired liver function</span>. For patients with a history of <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span> associated with past estrogen use or with pregnancy, caution should be exercised and in the case of recurrence, medication should be discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.5"></a><p></p>
<h3>5. <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">Hypothyroidism</span></h3>
<p class="First">Estrogen administration leads to increased thyroid-binding globulin (TBG) levels. Patients with <span class="product-label-link" type="condition" conceptid="4193309" conceptname="Thyroid function tests normal">normal thyroid function</span> can compensate for the increased TBG by making more thyroid hormone, thus maintaining free T<span class="Sub">4</span> and T<span class="Sub">3</span> serum concentrations in the normal range. Patients dependent on thyroid hormone replacement therapy who are also receiving estrogens may require increased doses of their thyroid replacement therapy. These patients should have their thyroid function monitored in order to maintain their free thyroid hormone levels in an acceptable range.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.6"></a><p></p>
<h3>6. <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span></h3>
<p class="First">Because estrogens may cause some degree of <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, patients with conditions that might be influenced by this factor, such as a cardiac or renal dysfunction, require careful observation when estrogens are prescribed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.7"></a><p></p>
<h3>7. <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span></h3>
<p class="First">Estrogens should be used with caution in individuals with severe <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.8"></a><p></p>
<h3>8. Ovarian cancer</h3>
<p class="First">The CE/MPA substudy of WHI reported that estrogen plus progestin increased the risk of ovarian cancer. After an average follow-up of 5.6 years, the relative risk for ovarian cancer for CE/MPA versus placebo was 1.58 (95% confidence interval 0.77 – 3.24) but was not statistically significant. The absolute risk for CE/MPA versus placebo was 20 versus 12 cases per 10,000 women-years. In some epidemiologic studies, the use of estrogen alone, in particular for ten or more years, has been associated with an increased risk of ovarian cancer. Other epidemiologic studies have not found these associations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.9"></a><p></p>
<h3>9. Exacerbation of <span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">endometriosis</span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">Endometriosis</span> may be exacerbated with administration of estrogens. A few cases of malignant transformation of residual endometrial implants have been reported in women treated post-hysterectomy with estrogen-alone therapy. For patients known to have residual <span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">endometriosis</span> post-hysterectomy, the addition of progestin should be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.10"></a><p></p>
<h3>10. Exacerbation of other conditions</h3>
<p class="First">Estrogens may cause an <span class="product-label-link" type="condition" conceptid="257581" conceptname="Exacerbation of asthma">exacerbation of asthma</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> or <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span>, <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>, and hepatic <span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangiomas</span> and should be used with caution in women with these conditions.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-6.2"></a><p></p>
<h2>B. PATIENT INFORMATION</h2>
<p class="First">Physicians are advised to discuss the PATIENT INFORMATION leaflet with patients for whom they prescribe DEPO-Estradiol.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="section-6.3"></a><p></p>
<h2>C. LABORATORY TESTS </h2>
<p class="First">Estrogen administration should be initiated at the lowest dose for the approved indication and then guided by clinical response, rather than by serum hormone levels (e.g., estradiol, FSH).</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="section-6.4"></a><p></p>
<h2>D. DRUG/LABORATORY TEST INTERACTIONS</h2>
<ol>
<li>Accelerated <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of anti-factor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased <span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">plasminogen</span> antigen and activity.</li>
<li>Increased thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone, as measured by protein-bound iodine (PBI), T4 levels (by column or by radioimmunoassay) or T3 levels by radioimmunoassay. T3 resin uptake is decreased, reflecting the elevated TBG. Free T4 and free T3 concentrations are unaltered. Patients on thyroid replacement therapy may require higher doses of thyroid hormone.</li>
<li>Other binding proteins may be elevated in serum, i.e., corticosteroid binding globulin (CBG), sex-hormone binding globulin (SHBG), leading to increased circulating corticosteroids and sex steroids, respectively. Free or biologically active hormone levels concentrations are unchanged. Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-anti-trypsin, <span class="product-label-link" type="condition" conceptid="4294533" conceptname="Ferroxidase">ceruloplasmin</span>).</li>
<li>Increased plasma HDL and HDL-<span class="Sub">2</span> subfraction concentrations, reduced LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> concentration, increased triglycerides levels.</li>
<li>Impaired glucose tolerance.</li>
<li>Reduced response to metyrapone test.</li>
<li>Reduced serum folate concentration.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-6.5"></a><p></p>
<h2>E. CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY</h2>
<p class="First">Long-term continuous administration of natural and synthetic estrogens in certain animal species increases the frequency of carcinomas of the breast, uterus, cervix, vagina, testis, and liver. (See <span class="Bold"><a href="#boxed_warning">BOXED WARINGS</a>, <a href="#warnings">WARNINGS</a></span> and <span class="Bold"><a href="#precautions">PRECAUTIONS</a>.)</span></p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-6.6"></a><p></p>
<h2>F. PREGNANCY</h2>
<p class="First">DEPO-Estradiol should not be used during pregnancy. See <span class="Bold"><a href="#contraindications">CONTRAINDICATIONS</a></span> and Boxed <span class="Bold"><a href="#boxed_warning">WARNINGS</a>.</span></p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-6.7"></a><p></p>
<h2>G. NURSING MOTHERS</h2>
<p class="First">Estrogen administration to nursing mothers has been shown to decrease the quantity and quality of the milk. Detectable amounts of estrogens have been identified in the milk of mothers receiving this drug. Caution should be exercised when DEPO-Estradiol is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="precautions_geriatric"></a><a name="section-6.8"></a><p></p>
<h2>H. GERIATRIC USE</h2>
<p class="First">In the Women's Health Initiative Memory Study, including 4,532 women 65 years of age and older, followed for an average of 4 years, 82% (n= 3,729) were 65 to 74 while 18% (n= 803) were 75 and over. Most women (80%) had no prior hormone therapy use. Women treated with conjugated estrogens plus medroxyprogesterone acetate were reported to have a two-fold increase in the risk of developing probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. Alzheimer's disease was the most common classification of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in both the conjugated estrogens plus medroxyprogesterone acetate group and the placebo group. Ninety percent of the cases of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> occurred in the 54% of women that were older than 70. (See <span class="Bold"><a href="#warnings_dementia">WARNINGS, <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></a>.)</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">See <span class="Bold"><a href="#boxed_warning">BOXED WARNINGS</a>, <a href="#warnings">WARNINGS</a></span> and <span class="Bold"><a href="#precautions">PRECAUTIONS</a>.</span></p>
<p>The following additional adverse reactions have been reported with estrogens and/or progestin therapy.</p>
<dl>
<dt class="Bold">1.</dt>
<dd>
<span class="Bold Italics Underline">Genitourinary system</span><br>Changes in <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> pattern and abnormal <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> or flow; breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, spotting; <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span>; increase in size of uterine leiomyomata; <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span> including <span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">vaginal candidiasis</span>; change in amount of cervical secretion; changes in cervical <span class="product-label-link" type="condition" conceptid="376132" conceptname="Ectropion">ectropion</span>; ovarian cancer; <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span>; endometrial cancer.</dd>
<dt class="Bold">2.</dt>
<dd>
<span class="Bold Italics Underline">Breasts</span><br><span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">Tenderness</span>, enlargement <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4181744" conceptname="Discharge from nipple">nipple discharge</span>, <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">galactorrhea</span>; <span class="product-label-link" type="condition" conceptid="78804" conceptname="Fibrocystic disease of breast">fibrocystic breast</span> changes; breast cancer.</dd>
<dt class="Bold">3.</dt>
<dd>
<span class="Bold Italics Underline">Cardiovascular</span><br>Deep and superficial <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span>; <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>; <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>; <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>; <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>; increase in blood pressure.</dd>
<dt class="Bold">4.</dt>
<dd>
<span class="Bold Italics Underline">Gastrointestinal</span><br><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>; <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span>; <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>; increased incidence of <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span>; <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, enlargement of hepatic <span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangiomas</span>.</dd>
<dt class="Bold">5.</dt>
<dd>
<span class="Bold Italics Underline">Skin</span><br><span class="product-label-link" type="condition" conceptid="4264234" conceptname="Chloasma">Chloasma</span> or <span class="product-label-link" type="condition" conceptid="4264234" conceptname="Chloasma">melasma</span> that may persist when drug is discontinued. <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">Erythema multiforme</span>; <span class="product-label-link" type="condition" conceptid="140176" conceptname="Erythema nodosum">erythema nodosum</span>; hemorrhagic <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">eruption</span>; loss of scalp hair; <span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">hirsutism</span>; <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.</dd>
<dt class="Bold">6.</dt>
<dd>
<span class="Bold Italics Underline">Eyes</span><br>Retinal vascular <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>; steepening of corneal curvature; intolerance to contact lenses.</dd>
<dt class="Bold">7.</dt>
<dd>
<span class="Bold Italics Underline">Central nervous system</span><br><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>; mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>; <span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">chorea</span>; <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>; mood disturbances; <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>; exacerbation of <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>.</dd>
<dt class="Bold">8.</dt>
<dd>
<span class="Bold Italics Underline">Miscellaneous</span><br>Increase or decrease in weight; reduced carbohydrate tolerance; aggravation of <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span>; <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>; changes in libido; <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgias</span>; <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>; anaphylactoid/<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> including <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>; <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>; <span class="product-label-link" type="condition" conceptid="257581" conceptname="Exacerbation of asthma">exacerbation of asthma</span>; increased triglycerides.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="section-8"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<p class="First">Chlorobutanol anhydrous (chloral derivative) added as a preservative may be habit forming.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Serious ill effects have not been reported following acute ingestion of large doses of estrogen-containing oral contraceptives by young children. Overdosage of estrogen may cause <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> may occur in females.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Italics">Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.</span></p>
<p><span class="Italics">Warming and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span> the vial should redissolve any crystals that may have formed during storage at temperatures lower than recommended.</span></p>
<p>DEPO-Estradiol INJECTION IS FOR INTRAMUSCULAR USE ONLY.</p>
<p>When estrogen is prescribed for a woman with a uterus, progestin should also be initiated to reduce the risk of endometrial cancer. A woman without a uterus does not need progestin. Use of estrogen, alone or in combination with a progestin, should be with the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman. Patients should be reevaluated periodically as clinically appropriate (e.g., 3-month to 6-month intervals) to determine if treatment is still necessary. (See <span class="Bold"><a href="#boxed_warning">BOXED WARNINGS</a></span> and <span class="Bold"><a href="#warnings">WARNINGS</a></span>.) For women who have a uterus, adequate diagnostic measures, such as endometrial sampling, when indicated, should be undertaken to rule out malignancy in cases of undiagnosed persistent or recurring abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>.</p>
<ol>
<li>Short-term cyclic use for treatment of moderate to severe vasomotor symptoms, vulval and vaginal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> associated with the <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>, the lowest dose and regimen that will control symptoms should be chosen and medication should be discontinued as promptly as possible.<br> <br>Attempts to discontinue or taper medication should be made at 3- to 6-month intervals. The usual dosage range is 1 to 5 mg injected every 3 to 4 weeks.</li>
<li>For treatment of female hypoestrogenism due to <span class="product-label-link" type="condition" conceptid="4167354" conceptname="Hypogonadism">hypogonadism</span> 1.5 to 2 mg injected at monthly intervals.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">DEPO-Estradiol Injection is available in the following concentration containing per mL:</p>
<p><span class="Bold">5 mg</span> estradiol cypionate; also 5.4 mg chlorobutanol anhydrous (chloral deriv.) added as preservative; in 913 mg cottonseed oil— in 5 mL vials, NDC 0009-0271-01.</p>
<p><span class="Bold">WARNING:</span> Chlorobutanol may be habit forming.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-11.1"></a><p></p>
<p class="First">Store at controlled room temperature 20° to 25° C (68° to 77° F) [see USP].</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-12"></a><p></p>
<h1>REFERENCES</h1>
<ol>
<li>Ziel HK, Finkle WD: Increased risk of endometrial carcinoma among users of conjugated estrogens. <span class="Italics">N Engl J Med 293</span>:1167–1170, 1975.</li>
<li>Smith DC, Prentice R, Thompson DJ, et al: Association of exogenous estrogen and endometrial carcinoma. <span class="Italics">N Engl J Med 293</span>:1164–1167, 1975.</li>
<li>Mack TM, Pike MC, Henderson BE, et al: Estrogens and endometrial cancer in a retirement community. <span class="Italics">N Engl J Med 294</span>:1262–1267, 1976.</li>
<li>Weiss NS, Szekely DR, Austin DF: Increasing incidence of endometrial cancer in the United States. <span class="Italics">N Engl J Med 294</span>:1259–1262, 1976.</li>
<li>Herbst AL, Ulfelder H, Poskanzer DC: Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. <span class="Italics">N Engl J Med 284</span>:878–881, 1971.</li>
<li>Greenwald P, Barlow JJ, Nasca PC, Burnett WS: Vaginal cancer after maternal treatment with synthetic estrogens. <span class="Italics">N Engl J Med 285</span>:390–392, 1971.</li>
<li>Lanier AP, Noller KL, Decker DG, Elveback LR, Kurland LT: Cancer and stilbestrol. A follow-up of 1,719 persons exposed to estrogens <span class="Italics">in utero</span> and born 1943–1959. <span class="Italics">Mayo Clin Proc 48</span>:793–799, 1973.</li>
<li>Herbst AL, Kurman RJ, Scully RE: Vaginal and cervical abnormalities after exposure to stilbestrol <span class="Italics">in utero. Obstet Gynecol 40</span>:287–298, 1972.</li>
<li>Herbst AL, Robboy SJ, Macdonald GJ, Scully RE: The effects of local progesterone on stilbestrol-associated <span class="product-label-link" type="condition" conceptid="4242227" conceptname="Vaginal adenosis">vaginal adenosis</span>. <span class="Italics">Am J Obstet Gynecol 118</span>:607–615, 1974.</li>
<li>Herbst AL, Poskanzer DC, Robboy SJ, Friedlander L, Scully RE: Prenatal exposure to stilbestrol. A prospective comparison of exposed female offspring with unexposed control. <span class="Italics">N Engl J Med 292</span>:334–339, 1975.</li>
<li>Stafl A, Mattingly RF, Foley DV, Fetherston WC: Clinical diagnosis of <span class="product-label-link" type="condition" conceptid="4242227" conceptname="Vaginal adenosis">vaginal adenosis</span>. <span class="Italics">Obstet Gynecol 43</span>:118–128, 1974.</li>
<li>Sherman AL, Goldrath M, Berlin A, et al: Cervical-<span class="product-label-link" type="condition" conceptid="4242227" conceptname="Vaginal adenosis">vaginal adenosis</span> after <span class="Italics">in utero</span> exposure to synthetic estrogens. <span class="Italics">Obstet Gynecol 44</span>:531545, 1974.</li>
<li>Gall, Kirman B, Stern J: Hormonal pregnancy tests and congenital malformation. <span class="Italics">Nature 216</span>:83, 1967.</li>
<li>Levy EP, Cohen A, Fraser FC: Hormone treatment during pregnancy and congenital heart defects. <span class="Italics">Lancet 1</span>:611, 1973.</li>
<li>Nora JJ, Nora AH: <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">Birth defects</span> and oral contraceptives. <span class="Italics">Lancet 1</span>:941–942, 1973.</li>
<li>Janerich DT, Piper JM, Glebatis DM: Oral contraceptives and congenital limb-reduction defects. <span class="Italics">N Engl J Med 291</span>:697–700, 1974.</li>
<li>Boston Collaborative Drug Surveillance Program: Surgically confirmed gall bladder disease, <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">venous thromboembolism</span>, and breast tumors in relation to post-menopausal estrogen therapy. <span class="Italics">N Engl J Med 290</span>:15–19, 1974.</li>
<li>Hoover R, Gray LA, Cole P, MacMahon B: Menopausal estrogens and breast cancer. <span class="Italics">N Engl J Med 295</span>:401–405, 1976.</li>
<li>Boston Collaborative Drug Surveillance Program: Oral contraceptives and venous thromboembolic disease, surgically confirmed gall bladder disease, and breast tumors. <span class="Italics">Lancet 1</span>:1399–1404, 1973.</li>
<li>Daniel DG, Campbell H, Turnbull AC: Puerperal <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span> and suppression of lactation. <span class="Italics">Lancet 2</span>:287–289, 1967.</li>
<li>The Veterans Administration Cooperative Urological Research Group: Carcinoma of the prostate: Treatment comparisons. <span class="Italics">J Urol 98</span>:516522, 1967.</li>
<li>Bailar JC: <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">Thromboembolism</span> and estrogen therapy. <span class="Italics">Lancet 2</span>:560, 1967.</li>
<li>Blackard CE, Doe RP, Mellinger GT, Byar DP: Incidence of cardiovascular disease and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in patients receiving diethylstilbestrol for carcinoma of the prostate. <span class="Italics">Cancer 26</span>:249–256, 1970.</li>
<li>Royal College of General Practitioners: Oral contraception and thromboembolic disease. <span class="Italics">J R Coll Gen Pract 13</span>:267–279, 1967.</li>
<li>Inman WHW, Vessey MP: Investigation of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> from pulmonary, coronary, and <span class="product-label-link" type="condition" conceptid="441874" conceptname="Cerebral thrombosis">cerebral thrombosis</span> and <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span> in women of childbearing age. <span class="Italics">Br Med J 2</span>:193–199, 1968.</li>
<li>Vessey MP, Doll R: Investigation of relation between use of oral contraceptives and thromboembolic disease. A further report. <span class="Italics">Br Med J 2</span>:651–657, 1969.</li>
<li>Sartwell PE, Masi AT, Arthes FG, et al: <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">Thromboembolism</span> and oral contraceptives: An epidemiologic case-control study. <span class="Italics">Am J Epidemiol 90</span>:365–380, 1969.</li>
<li>Collaborative Group for the Study of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> in Young Women: Oral contraception and increased risk of <span class="product-label-link" type="condition" conceptid="374384" conceptname="Cerebral ischemia">cerebral ischemia</span> or <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>. <span class="Italics">N Engl J Med 288</span>:871–878, 1973.</li>
<li>Collaborative Group for the Study of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> in Young Women: Oral contraceptives and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> in young women: Associated risk factors. <span class="Italics">JAMA 231</span>:718–722, 1975.</li>
<li>Mann JI, Inman WHW: Oral contraceptives and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>. <span class="Italics">Br Med J 2</span>:245–248, 1975.</li>
<li>Mann JI, Vessey MP, Thorogood M, Doll R: <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial infarction</span> in young women with special reference to oral contraceptive practice. <span class="Italics">Br Med J 2</span>:241–245, 1975.</li>
<li>Inman WHW, Vessey MP, Westerholm B, Engelund A: Thromboembolic disease and the steroidal content of oral contraceptives. <span class="Italics">Br Med J 2</span>:203–209, 1970.</li>
<li>Stolley PD, Tonascia JA, Tockman MS, et al: <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span> with low-estrogen oral contraceptives. <span class="Italics">Am J Epidemiol 102</span>:197–208, 1975.</li>
<li>Vessey MP, Doll R, Fairbairn AS, Glober G: Postoperative <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span> and the use of oral contraceptives. <span class="Italics">Br Med J 3</span>:123–126, 1970.</li>
<li>Greene GR, Sartwell PE: Oral contraceptive use in patients with <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span> following surgery, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> or <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. <span class="Italics">Am J Public Health 62</span>:680–685, 1972.</li>
<li>Rosenberg L, Armstrong B, Phil D, Jick H: <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial infarction</span> and estrogen therapy in post-menopausal women. <span class="Italics">N Engl J Med 294</span>:1256–1259, 1976.</li>
<li>Coronary Drug Project Research Group: The Coronary Drug Project: Initial findings leading to modifications of its research protocol. <span class="Italics">JAMA 214</span>:1303–1313, 1970.</li>
<li>Baum J, Holtz F, Bookstein JJ, Klein EW: Possible association between benign <span class="product-label-link" type="condition" conceptid="4101758" conceptname="Hepatocellular carcinoma">hepatomas</span> and oral contraceptives. <span class="Italics">Lancet 2</span>:926–929, 1973.</li>
<li>Mays ET, Christopherson WM, Mahr MM, Williams HC: Hepatic changes in young women ingesting contraceptive steroids. <span class="product-label-link" type="condition" conceptid="4043254" conceptname="Hemorrhage of liver">Hepatic hemorrhage</span> and primary hepatic tumors. <span class="Italics">JAMA 235</span>:730–732, 1976.</li>
<li>Edmondson HA, Henderson B, Benton B: Liver-cell <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> associated with use of oral contraceptives. <span class="Italics">N Engl J Med 294</span>:470–472, 1976.</li>
<li>Pfeffer RI, VanDenNoort S: Estrogen use and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> risk in post-menopausal women. <span class="Italics">Am J Epidemiol 103</span>:445–456, 1976.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">The text of the patient insert for estrogen-containing drug products is set forth below.</span></p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="section-14"></a><p></p>
<h1>PATIENT INFORMATION</h1>
<p class="First"><span class="Bold">DEPO-Estradiol<span class="Sup">®</span></span></p>
<p><span class="Bold">Brand of estradiol cypionate injection, USP</span></p>
<p>Read this PATIENT INFORMATION before you start taking DEPO-Estradiol and read what you get each time you refill DEPO-Estradiol. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.</p>
</div>
<div class="Warning">
<a name="section-15"></a><p></p>
<h1>WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT DEPO-ESTRADIOL (AN ESTROGEN HORMONE)?</h1>
<p class="First">Estrogens increase the chances of getting cancer of the uterus.</p>
<p>Report any unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> right away while you are taking estrogens. <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal bleeding</span> after <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> may be a warning sign of cancer of the uterine (womb). Your healthcare provider should check any unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> to find out the cause.</p>
<p>Do not use estrogens with or without progestins to prevent heart disease, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span>, or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>.</p>
<p>Using estrogens with or without progestins may increase your chances of getting <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, breast cancer, and blood clots. You and your healthcare provider should talk regularly about whether you still need treatment with DEPO-Estradiol.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15"></a><p></p>
<h1></h1>
<p class="First"><br><span class="Bold">What is DEPO-Estradiol?</span></p>
<p>Depo-Estradiol injection is an estrogen product. The information below is that which the U.S. Food and Drug Administration requires be provided for all patients taking estrogens. For further information ask your doctor.</p>
<p><br><span class="Bold">What is DEPO-Estradiol used for?</span></p>
<p>DEPO-Estradiol is used during and after <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> to:</p>
<ul class="Disc"><li>
<span class="Underline">reduce moderate or severe <span class="product-label-link" type="condition" conceptid="439082" conceptname="Menopausal syndrome">menopausal symptoms</span>.</span> Estrogens are hormones made by a woman's ovaries. The ovaries normally stop making estrogens when a woman is between 45 to 55 years old. This drop in body estrogen levels causes the "change of life" or <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> (end of monthly menstrual periods). Sometimes both ovaries are removed during an operation before natural <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> takes place, the sudden drop in estrogen levels causes "<span class="product-label-link" type="condition" conceptid="440155" conceptname="Postartificial menopausal syndrome">surgical menopause</span>."</li></ul>
<p>When the estrogen levels begin dropping, some women develop very uncomfortable symptoms, such as <span class="product-label-link" type="condition" conceptid="4141161" conceptname="Hot">feeling of warmth</span> in the face, neck and chest or sudden strong feelings of heat and <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> ("<span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span>" or "<span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span>"). Using estrogen drugs can help the body adjust to lower estrogen levels and reduce these symptoms. Most women have only mild <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> symptoms or none at all and do not need estrogen drugs for these symptoms.</p>
<ul class="Disc"><li>
<span class="Bold">treat moderate to severe <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, burning, and dryness in or around the vagina.</span><br>You and your healthcare provider should talk regularly about whether you still need treatment with DEPO-Estradiol to control these problems.</li></ul>
<p><br><span class="Bold">DEPO-Estradiol is also used to:</span></p>
<ul class="Disc"><li>treat certain conditions in women before <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> if their ovaries do not make enough estrogen.</li></ul>
<p><br><span class="Bold">Who should not take DEPO-Estradiol?</span></p>
<p>Do not start taking DEPO-Estradiol if you:</p>
<ul class="Disc">
<li><span class="Bold">have unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>.</span></li>
<li>
<span class="Bold">currently have or have had certain cancers.</span><br>Estrogens may increase the chances of getting certain types of cancers, including cancer of the breast or uterus. If you have or had cancer, talk with your healthcare provider about whether you should take DEPO-Estradiol.</li>
<li><span class="Bold">had a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> in the past year.</span></li>
<li><span class="Bold">currently have or have had blood clots.</span></li>
<li><span class="Bold">are allergic to DEPO-Estradiol or any of its ingredients.</span></li>
</ul>
<p>See the end of this leaflet for a list of ingredients in DEPO-Estradiol.</p>
<ul class="Disc"><li><span class="Bold">think you may be pregnant.</span></li></ul>
<p><span class="Bold">Tell your healthcare provider:</span></p>
<ul><li><span class="Bold">if you are breastfeeding.</span></li></ul>
<p>The hormone in DEPO-Estradiol can pass into your milk.</p>
<ul class="Disc">
<li>
<span class="Bold">about all of your medical problems.</span><br>Your healthcare provider may need to check you more carefully if you have certain conditions, such as <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> (<span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>), <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> (<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>), <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">endometriosis</span>, or problems with your heart, liver, thyroid, kidneys, or have high calcium levels in your blood.</li>
<li>
<span class="Bold">about all the medicines you take.</span><br>This includes prescription and nonprescription medicines, vitamins, and herbal supplements. Some medicines may affect how DEPO-ESTRADIOL works. DEPO-ESTRADIOL may also affect how your other medicines work.</li>
<li>
<span class="Bold">if you are going to have surgery or will be on bed rest.</span><br>You may need to stop taking estrogens.</li>
</ul>
<p><br><span class="Bold">How should I take DEPO-Estradiol?</span></p>
<p>Take DEPO-Estradiol as directed by your healthcare provider.</p>
<p>Estrogens should be used only as long as needed. You and your healthcare provider should talk regularly (for example, every 3 to 6 months) about whether you still need treatment with DEPO-ESTRADIOL.</p>
<p><br><span class="Bold">What are the possible side effects of estrogens?</span></p>
<p><span class="Bold">Less common but serious side effects include:</span></p>
<ul class="Disc">
<li>Breast cancer</li>
<li>Cancer of the uterus</li>
<li><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span></li>
<li><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Heart attack</span></li>
<li>Blood clots</li>
<li><span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder disease</span></li>
<li>Ovarian cancer</li>
</ul>
<p><span class="Bold">These are some of the warning signs of serious side effects:</span></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="80767" conceptname="Breast lump">Breast lumps</span></li>
<li>Unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> and faintness</li>
<li>Changes in speech</li>
<li>Severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span></li>
<li><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Shortness of breath</span></li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pains</span> in your legs</li>
<li>Changes in vision</li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></li>
</ul>
<p>Call your healthcare provider right away if you get any of these warning signs, or any other unusual symptom that concerns you.</p>
<p><span class="Bold">Common side effects include:</span></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">Breast pain</span></li>
<li>Irregular <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> or spotting</li>
<li>Stomach/<span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
</ul>
<p><span class="Bold">Other side effects include:</span></p>
<ul class="Disc">
<li>High blood pressure</li>
<li>Liver problems</li>
<li>High blood sugar</li>
<li><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span></li>
<li>Enlargement of benign tumors of the uterus ("<span class="product-label-link" type="condition" conceptid="197236" conceptname="Uterine leiomyoma">fibroids</span>")</li>
<li>Vaginal <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infections</span></li>
<li><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Hair loss</span></li>
</ul>
<p>These are not all the possible side effects of DEPO-Estradiol. For more information, ask your healthcare provider or pharmacist.</p>
<p><br><span class="Bold">What can I do to lower my chances of getting a serious side effect with DEPO-Estradiol?</span></p>
<ul class="Disc"><li>Talk with your healthcare provider regularly about whether you should continue taking DEPO-ESTRADIOL. If you have a uterus, talk to your healthcare provider about whether the addition of a progestin is right for you. See your healthcare provider right away if you get <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> while taking DEPO-ESTRADIOL. Have a breast exam and mammogram (breast X-ray) every year unless your healthcare provider tells you something else. If members of your family have had breast cancer or if you have ever had <span class="product-label-link" type="condition" conceptid="80767" conceptname="Breast lump">breast lumps</span> or an abnormal mammogram, you may need to have breast examinations more often. If you have high blood pressure, high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (fat in the blood), <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, are overweight, or if you use tobacco, you may have higher chances for getting heart disease. Ask your healthcare provider for ways to lower your chances for getting heart disease.</li></ul>
<p><br><span class="Bold">General information about safe and effective use of DEPO-Estradiol</span></p>
<p>Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not take DEPO-Estradiol for conditions for which it was not prescribed. Do not give DEPO-Estradiol to other people, even if they have the same symptoms you have. It may harm them. <span class="Bold">Keep DEPO-Estradiol out of the reach of children.</span></p>
<p><span class="Bold">This leaflet provides a summary of the most important information about DEPO-Estradiol. If you would like more information, talk with your healthcare provider or pharmacist. You can ask for information about DEPO-Estradiol that is written for health professionals. You can get more information by calling the toll free number 1-888-691-6813. You are cautioned to discuss very carefully with your doctor or healthcare provider all the possible risks and benefits of long-term estrogen and progestin treatment as they affect you personally.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Rx only</span></p>
<p><img alt="Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9a4229fd-fecd-4ac1-9c4f-6d442533457f&amp;name=depo-estradiol-02.jpg"></p>
<p>LAB-0083-3.0<br>October 2006</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 5 mg/mL Vial Carton</h1>
<p class="First">NDC 0009-0271-01<br><span class="Bold">Rx only</span></p>
<p><span class="Bold">1– 5 mL Vial</span></p>
<p><span class="Bold">Depo<span class="Sup">®</span>-Estradiol</span><br>estradiol cypionate<br>injection, USP</p>
<p><span class="Bold">5 mg/mL</span></p>
<p>For intramuscular use only</p>
<p><span class="Bold Italics">Pfizer Injectables</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 5 mg/mL Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9a4229fd-fecd-4ac1-9c4f-6d442533457f&amp;name=depo-estradiol-03.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 5 mg/mL Vial Label</h1>
<p class="First"><span class="Bold">5 mL Vial</span><br>NDC 0009-0271-01</p>
<p><span class="Bold">Depo<span class="Sup">®</span>-Estradiol</span><br>estradiol cypionate injection, USP</p>
<p><span class="Bold">5 mg/mL</span></p>
<p>For intramuscular use only<br>MADE IN USA<br>(includes foreign content)</p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 5 mg/mL Vial Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9a4229fd-fecd-4ac1-9c4f-6d442533457f&amp;name=depo-estradiol-04.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DEPO-ESTRADIOL 		
					</strong><br><span class="contentTableReg">estradiol cypionate injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0009-0271</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ESTRADIOL CYPIONATE</strong> (ESTRADIOL) </td>
<td class="formItem">ESTRADIOL CYPIONATE</td>
<td class="formItem">5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>COTTONSEED OIL</strong></td>
<td class="formItem">913 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CHLOROBUTANOL</strong></td>
<td class="formItem">5.4 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0009-0271-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA085470</td>
<td class="formItem">08/15/1979</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Pharmacia and Upjohn Company
							(829076566)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pharmacia and Upjohn Company</td>
<td class="formItem"></td>
<td class="formItem">829076566</td>
<td class="formItem">ANALYSIS(0009-0271), API MANUFACTURE(0009-0271), LABEL(0009-0271), MANUFACTURE(0009-0271), PACK(0009-0271)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>bd40c86d-8531-437d-90f4-5240da9f9640</div>
<div>Set id: 9a4229fd-fecd-4ac1-9c4f-6d442533457f</div>
<div>Version: 3</div>
<div>Effective Time: 20130820</div>
</div>
</div> <div class="DistributorName">Pharmacia and Upjohn Company</div></p>
</body></html>
